UnknownNot Applicable

Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months

France8 participantsStarted 2023-06-05

Plain-language summary

OZURDEX endophthalmitis is a rare and potentially very serious pathology. Different treatments can be carried out early and change the functional prognosis of the patient.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient who had endophtalmitis following an OZURDEX implant injection within 2 months Exclusion Criteria: * Intra oculaire procedure in the interval between the injection of OZURDEX and endophtalmitis

What they're measuring

Visual acuity

Timeframe: 2018 to 2023

Trial details

NCT IDNCT06268561

SponsorCentre Hospitalier Universitaire de Saint Etienne

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06

Contact for this trial

Thibaud GARCIN, MD PhD

(0)477829662 thibaud.garcin@chu-st-etienne.fr

View on ClinicalTrials.gov More Endophthalmitis trials